Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide

Prostate Cancer and Prostatic Diseases volume 4, pages 112–117 (2001)Cite this article

Abstract

The use, tolerability and efficacy of the non-steroidal anti-androgen nilutamide (Anandron®) in daily clinical practice was investigated in this 5-y project. In total 725 patients were recruited from 27 Dutch centres. The investigated population was very heterogeneous and different therapeutic options were reported. We may conclude that in general good results have been obtained, especially in first line combination therapy combined with luteinising hormone releasing hormone (LHRH) agonists. Patients with a good performance status at inclusion seem to benefit more from nilutamide combination therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Schröder FH et al. European randomised study of screening for prostate cancer, the Rotterdam pilot studies. Int J Cancer 1996 65 145–151.

    Article  Google Scholar 

  2. Huggins C, Hodge C. Studies on prostatic cancer. The effects of castration, oestrogen or androgen therapy on SAP in metastic cancer of the prostate. Cancer Res 1941 1 293–297.

    CAS  Google Scholar 

  3. Borgmann V et al Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach? Lancet 1982 15 1097–1099.

    Article  Google Scholar 

  4. Huggins S. Bilateral adrenalectomy in prostatic cancer. Ann Surg 1945 122 1031–1037.

    Article  Google Scholar 

  5. Harris MG, Coleman SG, Faulds D, Chrisp P. Nilutamide a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs & Aging 1993 3 9–25.

    Article  CAS  Google Scholar 

  6. Gezondheidsraad, Commissie Post marketing Surveillance. Post marketing surveillance in Nederland. The Hague: Rapport Gezondheidsraad 1991.

  7. Waller PC. Guidelines for company-sponsored safety assessment of marketed medicines (SAMM guidelines). Br J Clin Pharmacol 1994 38 95–97.

    Article  Google Scholar 

  8. Wesseling H. Nederland en ‘post marketing surveillance’ (The Netherlands and Post marketing surveillance). Ned Tijdschr Geneeskd 1992 136 7–8.

    CAS  PubMed  Google Scholar 

  9. Broekmans AW, Lekkerkerker JFF, Koning GHP, de Vree PH. Nieuwe regels voor het melden van bijwerkingen in Nederland na 1995. Ned Tijdschr Geneeskd 1996 140 1166–1167.

    CAS  PubMed  Google Scholar 

  10. LaBrie F, Dupont A, Belanger A. New approach in the treatment of prostatic cancer, complete instead of partial withdrawal of androgens. The Prostate 1983 4 579–594.

    Article  CAS  Google Scholar 

  11. Janknegt RA et al Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993 149 77–83.

    Article  CAS  Google Scholar 

  12. Bertagna C et al Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double blind trials (1056 patients). Br J Urol 1994 73 396–402.

    Article  CAS  Google Scholar 

  13. Dijkman GA, Janknegt RA, de Reijke TM, Debruyne FMJ. Long term efficacy and safety of nilutamide plus castration in advanced prostate cancer and the significance of early prostate specific antigen normalization. J Urol 1997 158 160–163.

    Article  CAS  Google Scholar 

  14. Miller JI et al The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992 147 956–961.

    Article  CAS  Google Scholar 

  15. Matzkin H et al Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 1992 70 2302–2309.

    Article  CAS  Google Scholar 

  16. Mulders PF et al Analysis of prognostic factors in disseminated prostatic cancer, an update. Cancer 1990 65 2758–2761.

    Article  CAS  Google Scholar 

  17. Decensi AU et al Monotherapy with nilutamide, a pure non-steroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991 146 377–381.

    Article  CAS  Google Scholar 

  18. Soloway MS. Combined androgen blockade: an optimal therapy for minimally advanced prostate cancer. Br J Urol 1998 81 87–95.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

CTO Oss, The Netherlands, did the statistical analysis.

List of investigators

HHR Bakker, Kennemer Gasthuis, Ijmuiden; C vd Beek, Academisch Ziekenhuis, Maastricht, Maastricht; J Brouwer/GF de Pagter, Rode Kruis Ziekenhuis, Heemskerk; KPJ Delaere, De Wever Ziekenhuis, Heerlen; WHH Ferwerda, Alg Ziekenhuis Heerenveen, Heerenveen; S Geluk/JH Vriesde, Streekziekenhuis Walcheren, Vlissingen; R Gilhuis, Beatrixziekenhuis, Gorinchem; JM Groen, Spaarne Ziekenhuis, Haarlem; H Groenewold/JJ Visser/HMM Zweers, Twenteborg Ziekenhuis, Almelo; DH Helmhout, Bleuland Ziekenhuis, Gouda; H Jansen, Ziekenhuis De Baronie, Breda; GSS Khoe, Medisch Spectrum Twente, Enschede; M Kiewiet de Jonge, Rode Kruis Ziekenhuis, Den Haag; WJ Levens, St. Joseph Ziekenhuis, Veldhoven; MTWT Lock, Academisch Ziekenhuis Utrecht, Utrecht; F van Meenen, Holy Ziekenhuis, Vlaardingen; HC Pull, St. Ziekenhuis Lievensberg, Bergen op Zoom; LMH Schreinemachers, Bosch Medicentrum, Den Bosch; AJ Smans, St. Anna Ziekenhuis, Oss; E Timmer/EMM Williams, Ruwaard van Putten Ziekenhuis, Spijkenisse; NP Tjon Pian Gi, Martini Ziekenhuis, Groningen; AFGVM Ypma/GAEM Buijs, St Deventer Ziekenhuizen, Deventer; AGM Zeegers, Drechtsteden Ziekenhuizen, Dordrecht.

Author information

Authors and Affiliations

  1. Medical Department, Aventis Pharma B.V., Hoevelaken, The Netherlands

    EMC Schasfoort

  2. Department of Urology, University of Maastricht, The Netherlands

    C van de Beek

  3. Department of Urology, Free University of Amsterdam, The Netherlands

    DWW Newling

Authors
  1. EMC Schasfoort
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C van de Beek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. DWW Newling
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schasfoort, E., van de Beek, C. & Newling, D. Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide. Prostate Cancer Prostatic Dis 4, 112–117 (2001). https://doi.org/10.1038/sj.pcan.4500516

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500516

Keywords

Search

Advanced search

Quick links